Peptides for Focus & Productivity
"I can't concentrate" describes at least four different problems, and they don't respond to the same things. Here is how to work out which one you have — and an honest read on whether any peptide addresses it.
This guide covers the compounds most often used for attention and mental performance, the quality of the evidence behind each, and the non-pharmacological factors that outperform all of them. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
Most pages on this topic hand you a ranked list of compounds and let you pick. That skips the step that determines whether any of them will do anything for you.
Attention is not one system. Starting a task, staying on it, filtering distractions and having the physical energy to keep going are separate functions with separate failure modes. A compound that helps one may do nothing at all for another — and if the actual cause is six hours of broken sleep, none of them will touch it.
Which Problem Do You Have?
Before looking at any compound, work out what your version of "poor focus" actually looks like. The four patterns below cover most cases, and they point in different directions.
Simplified framing. Patterns overlap in practice, and more than one can be running at once.
The orange boxes matter most. Persistent difficulty starting tasks that has been there since childhood is what ADHD looks like, and it responds to treatments with decades of trial evidence behind them — not to a research peptide. Physical fatigue that arrives on a schedule is what anaemia, thyroid dysfunction, sleep apnea and B12 deficiency look like, and all four are cheap to test for and treatable.
None of that is a reason to avoid this topic. It is a reason to spend an afternoon ruling things out before spending months experimenting.
Matching Bottleneck to Approach
| What it feels like | Most likely driver | Where to look |
|---|---|---|
| Can't begin, even on things you want to do | Motivation circuitry; possible ADHD or low mood | Clinical assessment first. Semax is the compound most discussed here, on the thinnest possible evidence |
| Focus collapses after 20–30 minutes | Sleep debt; excessive cognitive load; poor recovery | Sleep quality before anything else — see peptides for sleep |
| Constantly pulled off-task by worry | Anxiety and arousal, not attention | Anxiety is the target. See peptides for anxiety and stress; Selank is the relevant compound |
| Sharp early, physically flat by mid-afternoon | Metabolic, haematological or endocrine | Bloodwork. Mitochondrial and NAD+ compounds get discussed here, with limited support |
| Foggy since a specific event — illness, injury, medication change | Something changed and needs identifying | A doctor, not a supplier |
What the Evidence Actually Looks Like
This category has an unusual and specific evidence problem, and understanding it is worth more than any individual compound summary.
The two most-discussed cognitive peptides, Semax and Selank, were both developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. Both are registered prescription medicines in Russia — Semax since the mid-1990s for stroke recovery and cognitive impairment, Selank since 2009 for generalised anxiety disorder and neurasthenia. That is a real regulatory approval in a real jurisdiction, based on real clinical trials.
The trials are almost entirely Russian-language, mostly small, methodologically variable by current standards, and have not been independently replicated in Western trials. So the honest position sits between two wrong ones. These are not unstudied compounds pulled off a forum. They are also not compounds whose effects in healthy people have been demonstrated to the standard you would expect of a medicine.
A distinction the marketing tends to blur
What the Russian trials mostly studied was restoring function in people who had lost it — after a stroke, with cerebrovascular cognitive impairment, with diagnosed anxiety disorders. Enhancing performance in a healthy adult who simply wants to concentrate better at work is a different question, and it has not been answered by large, replicated, high-quality trials for any compound on this page. When the FDA reviewed Semax in 2026, the healthy-cognition claims were not the basis of the review, and the agency judged the evidence for the indications it did examine insufficient to establish effectiveness.
The Compounds
Semax
Met-Glu-His-Phe-Pro-Gly-Pro — a synthetic ACTH(4-7) fragment with a stabilising Pro-Gly-Pro tail
Semax was engineered to keep the neurological activity of ACTH while dropping its hormonal effect on the adrenal glands, and it is the compound with the strongest position in this category — which says as much about the category as about Semax.
What it does mechanistically
Its best-replicated action is upregulating BDNF and NGF, two growth factors central to synaptic plasticity. This has been reproduced across multiple laboratories in rodents, in both healthy and injured brain tissue. It also modulates dopaminergic and serotonergic transmission. Notably it is not a stimulant: it does not force catecholamine release, and its cognitive effects are described as building over days rather than arriving in an hour.
What the human research shows
Russian clinical trials in ischaemic stroke report improved neurological recovery scores when given early, and a 2018 study in 110 post-stroke patients found raised plasma BDNF correlating with recovery trajectory. Smaller Russian studies in students under academic load and in operators performing sustained-attention tasks report preserved vigilance and reaction time. Effect sizes are modest and the studies are small.
The honest caveat
Semax is frequently discussed as an ADHD option. The published basis for that is a single 2007 hypothesis paper — not a trial. No controlled clinical trial of Semax in ADHD has been published. Full detail in our Semax complete guide.
Selank
Thr-Lys-Pro-Arg-Pro-Gly-Pro — a stabilised analogue of tuftsin, an immune peptide fragment of IgG
Selank belongs on this page for a reason worth stating plainly: it is not a focus compound. It is an anxiolytic, and its reputation for improving cognition may be largely downstream of that.
Why that matters here
Anxiety degrades working memory, narrows attention and impairs decision quality. If worry is what keeps pulling you off-task, reducing the worry looks a great deal like improving focus — but you have addressed a different mechanism. Recognising which of these describes you is the whole point of the first section of this page.
What the human research shows
The anchor study is a 2008 Russian trial of 62 patients with generalised anxiety disorder or neurasthenia, comparing Selank in 30 patients against the benzodiazepine medazepam in 32. Anxiolytic efficacy was reported as comparable, with Selank additionally showing anti-fatigue and mild stimulant-like effects and without benzodiazepine sedation. Later Russian work reports attention and working-memory improvements in small samples. Again: small, short, single research tradition, unreplicated in the West.
Where to read more
Our Selank complete guide covers it in depth, and the Selank vs Semax comparison covers choosing between them.
Adamax
An adamantyl-modified Semax analogue
Adamax attaches an adamantane group to the Semax scaffold, an approach intended to extend the pharmacokinetic profile of the parent molecule. It is an active research direction rather than a settled one.
The state of play
Whatever evidence problems Semax has, Adamax has more of them. There is no published human trial, no regulatory approval anywhere, and no established dose. Anyone using it is extrapolating from Semax and hoping the modification behaves as intended. That is a legitimate thing to find interesting and a poor basis for expecting a specific result. See our Adamax complete guide.
Compounds discussed for the energy side
Where the bottleneck is physical rather than cognitive, a different set comes up — and the evidence here is generally weaker still for focus specifically, because these compounds were not studied for attention.
NAD+
Discussed for mental clarity and fatigue. Human trials exist but results are mixed, and the cognitive endpoints are not where the evidence is strongest.
SS-31
Targets mitochondrial membrane function. Phase 2/3 human trials exist for other indications, with mixed results. Nothing on attention specifically.
MOTS-c
Metabolic rather than cognitive. No interventional human data at all, and it is named on the WADA banned list.
DSIP
Belongs here only indirectly. If broken sleep is the cause of your daytime fog, sleep is the lever — though DSIP's own evidence is thin.
Side by Side
| Compound | Primary target | Human evidence | Regulatory status |
|---|---|---|---|
| Semax | Neuroplasticity via BDNF; attention | Russian trials, mostly in stroke and cognitive impairment; unreplicated | Registered in Russia; not approved in the US or EU |
| Selank | Anxiety and stress reactivity | Russian trials in GAD; one benzodiazepine comparison; unreplicated | Registered in Russia since 2009; not approved in the US or EU |
| Adamax | Same scaffold as Semax, longer acting | None published | Not approved anywhere |
| NAD+ and mitochondrial compounds | Cellular energy | Mixed; not focused on attention endpoints | Not approved for cognitive indications |
| Caffeine | Adenosine blockade; alertness | Extensively studied and replicated | Unrestricted |
That last row is not a joke. Caffeine has more replicated evidence for alertness and vigilance than everything above it combined, and anyone reaching for a research peptide before optimising something that basic has skipped a step.
What Outperforms All of It
Any honest page on this subject has to say the boring part, so here it is compressed.
- Sleep is the whole game. A single short night measurably degrades attention, working memory and error rates the next day. No compound on this page compensates for chronic sleep restriction, and several make it worse if dosed late.
- Exercise has the strongest evidence of anything here for cognitive function, including the BDNF pathway that makes Semax interesting in the first place. Training raises BDNF reliably and for free.
- Cognitive load is a design problem. Attention that collapses after twenty minutes on fragmented, notification-heavy work is behaving normally. That is not a neurochemistry problem.
- Alcohol wrecks the sleep that determines tomorrow's focus, even in amounts that do not feel excessive.
- Untreated conditions stay untreated. Sleep apnea, thyroid dysfunction, anaemia, depression and ADHD all present as poor concentration, and all have real treatments.
Anyone who has these in place and still wants to experiment is in a reasonable position. Anyone who does not is buying a compound to solve a problem it was never going to touch.
Testing Whether It Works
Cognitive effects are the easiest thing in the world to imagine, which makes this category unusually prone to self-deception. A few practical steps make the difference between knowing and believing.
Get a baseline first
Two weeks of tracking before you change anything. Without it you are comparing today against a memory, and memory is generous.
Pick one measurable thing
Deep-work minutes, tasks completed, a timed task you repeat. Something countable beats "felt sharper," which is what expectation produces on its own.
Change one variable
Starting two compounds in the same week guarantees you learn nothing about either. Stagger them.
Expect the first week to lie
Novelty and expectation produce a real subjective lift that fades. Judge at three to four weeks, not on day three.
Safety & Regulatory
Semax and Selank both have reassuring tolerability records in the Russian clinical literature, with no dependence or withdrawal syndrome reported and no sedation from Selank. That record comes from short courses in supervised settings, which is not the same as an established long-term safety profile.
Where caution genuinely applies
If you take psychiatric medication. Interaction studies with SSRIs, SNRIs, stimulants and MAOIs are essentially absent, and both compounds touch serotonergic and dopaminergic signalling. This is a prescriber conversation, not a forum one — see our page on peptide drug interactions. If you suspect ADHD or depression. Self-medicating an undiagnosed condition with an unapproved compound delays a diagnosis that would give you access to treatments that actually work. Get assessed first. If your focus problems came with low mood, hopelessness or loss of interest, that combination points at something a peptide does not address, and it is worth talking to someone about. Competitive athletes. Neither compound is approved by any governmental health authority for human therapeutic use outside Russia, which places them within WADA's S0 category — prohibited at all times. Confirm with your national anti-doping organisation.
On regulatory status more broadly: in July 2026 the FDA's Pharmacy Compounding Advisory Committee issued a favourable recommendation for Semax regarding the 503A bulks list. That recommendation is advisory and non-binding, does not change the compound's legal status, and — importantly for this page — was not based on healthy-person cognitive enhancement claims. Our guide to research peptides versus pharmaceutical peptides explains what "research compound" means in practice.
Common Questions
Which is the best peptide for focus?
Semax has the most evidence behind it, and the gap between it and everything else in this category is real. Whether that makes it good enough to expect a result is a separate question, and the honest answer for a healthy adult is that nobody has demonstrated it to a modern standard.
Are these like Adderall or modafinil?
No, and the difference is mechanistic rather than a matter of degree. Stimulants act on catecholamine systems and produce an effect you feel within an hour. Semax works through gene expression and growth factor signalling, with effects described as accumulating over days. It also has vastly less evidence than either of those medicines, both of which are approved and extensively trialled.
Should I use Semax and Selank together?
It is the most common pairing, on the logic that one addresses cognitive output and the other the anxious baseline that undermines it. The rationale is coherent and the combination has not been formally studied. If you do try both, introduce them separately — otherwise you will not know which is doing anything, or which is causing a problem.
How long before I notice anything?
The Russian clinical protocols generally run courses of around ten to fourteen days, which tells you something about the expected timescale. Anyone reporting a dramatic effect on day one is describing expectation more than pharmacology, given the proposed mechanism.
Why is everything Russian?
Both compounds came from the same Moscow institute, developed within a research tradition that invested heavily in regulatory peptides while Western pharma went elsewhere. It is a genuine body of work, not a red flag by itself. The limitation is that a single research tradition producing all the positive results is exactly the situation independent replication exists to check, and that check has not happened.
Do these help with brain fog after illness?
Post-viral and post-illness cognitive symptoms are an active research area with no established treatment, and no peptide has been shown to resolve them. If fog started with a specific illness and has persisted, that is worth investigating medically rather than treating speculatively.
Is intranasal better than injection?
Intranasal is the route used in essentially all the Russian clinical work for both compounds, so it is the route the evidence describes. Subcutaneous versions circulate in the research market, but the trial data does not transfer cleanly between routes, and no comparison has been published.
Will I build tolerance?
No tolerance or withdrawal has been reported for either compound in the Russian clinical literature, which is one of the more genuinely favourable things about them. Cycling schedules circulating online come from general convention rather than from any published finding about desensitisation to these specific compounds.
What does Peptides Costa Rica carry for this?
The relevant products are Semax, Selank and Adamax, with current pricing and stock on each page, and five or more vials of the same product carrying an automatic 15% discount. Our broader cognitive function range covers the rest.
Is any of this legal in Costa Rica?
These are sold here as research compounds and are not approved as finished pharmaceutical drugs by the Ministerio de Salud, the FDA or the EMA — regardless of their prescription status in Russia. Our FAQ page covers ordering locally.
Not sure which problem you're solving?
Tell us what your version of poor focus actually looks like and we'll give you an honest read — including when the answer is "see a doctor first" or "fix your sleep." No pressure, no upsell.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. Semax and Selank are registered prescription medicines in the Russian Federation but are not approved by the FDA, the EMA, or Costa Rica's Ministerio de Salud; Adamax holds no regulatory approval in any jurisdiction. All are sold here as research compounds intended for laboratory and scientific study. None is a treatment for ADHD, depression, anxiety disorders, cognitive impairment, post-viral fatigue, or any other condition. The human evidence described here derives overwhelmingly from Russian-language clinical trials that are small, methodologically variable by contemporary standards, and not independently replicated in Western trials; efficacy for cognitive enhancement in healthy adults has not been established. In July 2026 the FDA's Pharmacy Compounding Advisory Committee issued a favourable recommendation for Semax regarding the 503A Bulks List; that recommendation is advisory, non-binding, does not change the compound's legal status, and did not rest on healthy-person cognitive claims. No dosing figures appear on this page by design. No interaction studies exist for these compounds with SSRIs, SNRIs, stimulants, MAOIs or other psychiatric medication, and anyone taking such medication should consult their prescriber before use. Persistent difficulty concentrating can indicate an underlying medical or psychiatric condition — including sleep apnea, thyroid dysfunction, anaemia, ADHD or depression — that requires diagnosis and has established treatments; these should be investigated before or alongside any compound. Both compounds fall within WADA's S0 non-approved substances category and should be treated as prohibited in tested sport. Always consult a qualified healthcare professional before beginning any peptide protocol. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- Zhurnal Nevrologii i Psikhiatrii (Gusev, Martynov et al., 2018): Study of 110 post-stroke patients reporting elevated plasma BDNF with Semax administration and correlation with functional recovery.
- Russian clinical literature on Semax in acute ischaemic stroke (Gusev et al., 2001 onward): Reported improvements in neurological outcome scores with early intranasal administration.
- Neurochemical Research and related preclinical literature: Semax upregulates BDNF and NGF expression in hippocampus and frontal cortex, with effects persisting beyond the peptide's plasma half-life, and modulates dopaminergic and serotonergic transmission.
- Alzheimer's Drug Discovery Foundation, Cognitive Vitality report on Semax: Summary of the preclinical and clinical evidence base and its limitations.
- Medical Hypotheses (Tsai, 2007): Hypothesis paper proposing Semax as a candidate for ADHD — mechanistic rationale only, with no controlled clinical trial published since.
- Zhurnal Nevrologii i Psikhiatrii (Zozulia, Seredenin et al., 2008): Trial of 62 patients with generalised anxiety disorder or neurasthenia comparing Selank with medazepam; comparable anxiolytic effect with additional antiasthenic and stimulant-like properties reported.
- Frontiers in Pharmacology and Institute of Molecular Genetics publications: Selank's structure as a Pro-Gly-Pro-stabilised tuftsin analogue, GABAergic gene-expression effects and enkephalin-degradation inhibition.
- Russian Federation Ministry of Health registration records: Semax registered for ischaemic stroke and cognitive impairment; Selank registered in 2009 for generalised anxiety disorder and neurasthenia.
- U.S. Food and Drug Administration: 503A bulk drug substances review and the July 2026 Pharmacy Compounding Advisory Committee proceedings on Semax.
- World Anti-Doping Agency: Prohibited List, section S0, covering pharmacological substances without approval by any governmental health authority for human therapeutic use.
